STRATEC Biomedical AG
Avatud
17.7 -1.23
Ülevaade
Aktsiahinna muutus
24h
Min
17.38
Max
18.18
Sissetulek | 2.6M -1.7M |
|---|---|
Müük | -22M 53M |
P/E Sektori keskmine | 14.63 30.487 |
Aktsiakasum | -0.357 |
Dividenditootlus | 3.57 |
Kasumimarginaal | -3.206 |
Töötajad | 1,343 |
EBITDA | -6.7M 4.1M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +57.3% upside |
Dividenditootlus Sektori keskmine | 3.57% 3.24% |
|---|---|
Järgmine tulemuste avaldamine | 14. aug 2026 |
Turukapital | -1.9M 212M |
|---|---|
Eelmine avamishind | 18.93 |
Eelmine sulgemishind | 17.7 |
STRATEC Biomedical AG Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest STRATEC Biomedical AG
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
